Background: This multicenter phase II trial was conducted in order to evaluate the efficacy and toxicity of the subcutaneous route of administration of rIL-2 in the treatment of patients with metastatic renal cell carcinoma and to check whether an increased cumulative dose of rIL-2 increases efficacy.
Summary
Background: This multicenter phase II trial was conducted in order to evaluate the efficacy and toxicity of the subcutaneous route of administration of rIL-2 in the treatment of patients with metastatic renal cell carcinoma and to check whether an increased cumulative dose of rIL-2 increases efficacy.
Patients and methods: Thirty-nine patients with metastatic renal cell carcinoma were included in this study. During the induction period, rIL-2 was administered subcutaneously 5 days a week for 8 weeks. The weekly dosages were 90 MTU during weeks 1 and 6; 63 MTU during weeks 2 to 4 and 7 to 9. After evaluation, responders and patients with stable disease received maintenance treatment which was discontinued upon the appearance of disease progression or unacceptable toxicity. During the maintenance period, rIL-2 was administered 5 days a week for 4 weeks followed by a 2-week rest period. The weekly dosages were 90 MIU in week 1 and 63 MIU in weeks 2 to 4.
Results: After completion of induction treatment, 7 of 39 evaluable patients (18%) had objective responses (95% CI: 9% to 37%) with one complete response. Treatment was interrupted or reduced due to toxicity for seven patients: Neuropsychiatric symptoms (3 patients), joint pain (1 patient), major asthenia and anorexia (1 patient), stroke (1 patient), and septicemia (1 patient). Other systemic side effects in the remaining patients were acceptable. Seventeen patients received maintenance treatment. In none of the patients did the response status improve during this maintenance period. The median follow-up of all of the patients included was 19 months. The one-and two-year survivals were 65% and 33%, respectively, ad the median duration of response was 11 months (5 to 16+).
Conclusions:
This multicentric study confirms the efficacy of subcutaneously-administered rIL-2 in patients with metastatic renal cell carcinoma in terms of both response rate and survival. The role of a maintenance therapy needs further evaluation.
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The prognosis of metastatic renal cell carcinoma is very poor. Since the mid-1980s, recombinant interleukin-2 (rIL-2) has been used to treat patients with metastatic renal cell carcinoma. The initial protocols were based on the principles of chemotherapy administration, with intravenous bolus or continuous infusion of maximal tolerable doses [1, 2] . These studies demonstrated (depending on schedule), objective response rates of 15%-30% and complete response rates of 3%-5%. These protocols produced pulmonary, renal, cardiac and hemodynamic toxic effects requiring hospitalization, sometimes even in an intensive care unit. In order to improve tolerance, many authors have proposed that rIL-2 be subcutaneously administered on an outpatient basis [3, 4] . The results of these monocentric studies show that the subcutaneous route of administration has comparable efficacy, with objective response rates of 20% to 29% and complete response rates of 2% to 5%, with less toxicity.
We report the results of our phase II trial using rIL-2 given subcutaneously in patients with metastatic renal cell carcinoma The original aim of our multicentric study was to test the dose/efficacy concept by giving, over a 10-week period, a cumulative dose of rIL-2 analogous to that administered intravenously over the same duration of time according to the reference protocol of West etal. [2] .
Patients and methods
Patients with progressive, histologjcally proven, metastatic renal cell carcinoma and clinically measurable or evaluable disease were included in this study. The study was approved by the Paris Necker Enfants-Malades ethical committee, and patients were entered after their written informed consent was obtained. Those with brain metastases, second neoplasms, functional performance status (PS) >2, uncontrolled cardiovascular disease (congestive heart failure, coronary artery disease), severe renal dysfunction or who had previously been treated with rIL-2 were excluded.
Prior to study entry, each patient's disease stage was determined by full clinical examination, determination of blood cell counts, serum electrolytes, liver, renal and thyroid functions, chest X-ray, technetium pyrophosphate bone scan, and thoracic, abdominal and brain computed tomographic scanning. During the treatment, tumor volume was evaluated clinically and radiologically after the induction period and after the second, fourth, and sixth maintenance cycles.
The rIL-2 (Aldesleukin, Chiron, BV, Amsterdam, The Netherlands) was administered subcutaneously during the first and sixth weeks at a dose of 9 million international units (MIU), twice daily for 5 consecutive days and during the second, third, fourth, seventh, eighth, and ninth weeks at 9 MIU twice daily, on days 1 and 2, followed by 9 MIU once daily, on days 3, 4, and 5. The fifth week was free of treatment The daily dose of rIL-2 was reduced to 9 MIU in patients who developed severe toxicity (grade HI or IV). After induction evaluation and a 2-week rest period, in the absence of progression or unacceptable toxicity despite reduction of the rIL-2 dose, patients received maintenance therapy until progression or the advent of unacceptable toxic effects (grades IH or IV). Maintenance therapy was administered for a maximum of 7 cycles. Each cycle of the maintenance phase was separated by a 2-week rest period. During each maintenance cycle, rIL-2 was given subcutaneously on the same schedule as during the first, second, third, and fourth induction weeks. Paracetamol (500 mg orally every 4 to 6 hours) was given concomitantly in an attempt to ameliorate pyretic reactions.
Statistical analysis
Clinical response and toxicity were evaluated according to WHO criteria. Complete response (CR) was defined as the complete disappearance of all clinical and/or radiological disease for at least 4 weeks; partial response (PR) was defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of measurable lesions for at least one month; stable disease (SD) was defined as a decrease of less than 50% or an increase of less than 25% in measurable lesions; progressive disease (PD) was defined as an increase of more than 25% or the development of new lesions. Responses were evaluated by investigators as well as by independent reviewers to assess the results of treatment
The duration of response was calculated from the day the response was first documented to the day of documented progressive disease. The overall survival was calculated from the start of treatment Survival curves were plotted by using the Kaplan-Meier method and statistical differences were estimated using the log-rank test
Results

Patient characteristics
From April 1993 to April 1994, 39 patients with metastatic renal cell carcinoma, from 11 different centers, were included in this study. The initial characteristics of these patients are summarized in Table 1 . Eleven of these patients had previously received treatment: radiotherapy (n -4), and/or chemotherapy (n -6), and/or alpha interferon therapy (n ™ 10). According to Palmer et al. classification [5] , 3 patients (8%) had no poorprognosis factors, 15 (38%) had 1,11 (28%) had 2 and 10 (26%) had 3 poor-prognosis factors.
Delivered dose and toxicity
During the induction period, the cumulative planned dosage of rIL-2 administered subcutaneously was 558 MIU. For 5 of the 39 patients treatment had to be interrupted due to an obvious progression of the disease. For the 39 patients the mean cumulative dose of rIL-2 was 489 MIU (87% of the planned dose). Seven patients received 29%, 44%, 50%, 72%, 82%, 82% and 90% of the planned dose because treatment was interrupted or decreased due to toxicity. These toxic effects included neuropsychiatric manifestations (3 cases), stroke (1 case) septicemia (1 case) joint pain (1 case) and major weakness (1 case). Table 2 summarizes the side effects observed during the induction phase. There were five instances of thyroid dysfunction, namely, biological and clinical hypothyroidism in 2 patients requiring substitute treatments, and biologica 1 hyperthy- 
" Painful swelling at the injection site. roidism in 3. All of these problems disappeared within a few weeks after the completion of rIL-2 treatment. None of the patients developed hemodynamic or grade HI or IV renal toxicity (WHO) during the induction phase.
Response to induction treatment
All 39 patients were evaluable for response. Seven patients (18%) had objective responses, and there was one complete response (95 confidence limit 9% to 37%); 17 patients (43%) had stabilization of their disease and 15 (38%) tumor progression. The sites of objective response were lymph nodes (3/19), pulmonary metastases (8/24) and primary renal tumor (1/2).
Maintenance period
Of the 24 patients with objective response or stable disease at the completion of the induction period, 17 received a maintenance treatment For the 7 others, treatment was interrupted because of toxicity during the induction phase (5 cases) or by the patient's decision (2 cases). Seventeen patients (pts) received 1 cycle; 13 pts: 2 cycles; 10 pts: 3 cycles; 7 pts: 5 cycles; 5 pts: 6 cycles and 3 pts received 7 cycles. The maintenance therapy was interrupted in 11 patients because of an obvious progression of the disease, and by the patient's decision in 3 cases. A decrease in doses and/or a delay of 1-2 weeks in the treatment occurred in 8 patients because of side effects. During this maintenance period, one grade m toxic effect (infection) was observed. All other side effects were of grades I or II (WHO). In none of the patients was the response status better than the one at the end of the induction phase.
Progression and survival
The median follow-up of all included patients was 19 months. The response durations in the 7 responding patients were 5, 9, 11, 12, 13, 15+, 16+ months. The overall one-year survival and two-year survival were 65% (CI: 0.2437) and 33%, respectively. The one-year survivals for responders and non-responders were, respectively, 100% and 58% (P: 0.05). No significant differences in terms of survival were observed with respect to functional performance status, number of metastatic sites, the time between diagnosis and treatment of the metastatic disease and to administration of maintenance therapy.
Discussion
Recombinant interleukin-2 has been used since 1984 for the treatment of metastatic renal cell carcinoma. The response rates with the intravenous route of administration schedules are around 20% [1, 2, 6 ] with a benefit in terms of survival [7] . The protocols using high doses of rIL-2 given by bolus have significant toxic effects requiring hospitalization, sometimes even in an intensive care unit. Continuous infusion, with intermediate doses of rIL-2, improves tolerance but requires a close follow-up on an in-patient basis.
Since the beginning of the 1990s, several authors have used the subcutaneous route of administration with lower doses of rIL-2. Due to very low toxicity, it has been possible to perform these subcutaneous trials on an out-patient basis. The efficacy, based on the response rates, seems identical to those observed with the intravenous schedules. This modality allows the treatment of older patients, or patients with cardiac or renal dysfunction who are usually excluded from intravenous programs [4] .
Sleijfer et al., in their subcutaneous program, obtained a response rate of 20% with cumulative doses of rIL-2 between 306 MIU and 450 MIU according to the four-or six-week regimen [4] . Lissoni et al. reported a response rate of 29% after six weeks of treatment using a cumulative dose of 216 MIU [3] . The continuous infusion schedule as proposed by W.H. West allowed the administration of 612 MIU over 10 weeks with response rates of around 20%. In this study, during the 10 week induction period the patients received 489 MIU (87% of the planned dose: 558 MIU). These doses did not improve the efficacy (18% of objective response rate) and increased the toxicity, but the median survival (20 months) and the two-year survival (33%) observed with this program seem promising.
No improvement was observed during maintenance treatment among the 17 patients with objective responses or stabilization of disease. Sleijfer and Lissoni did not report data on the evolution of the disease status during the maintenance therapy. The role of such a treatment in patients with metastatic renal cell carci-noma with an objective response or stabilization should be evaluated in further studies.
In conclusion, this multicentric study confirms the efficacy of the subcutaneous rIL-2 programs in patients with metastatic renal cell carcinoma, with a response rate of around 20%, similar to those already published. Moreover, to our knowledge, this study is the first to confirm in terms of survival, the efficacy of subcutaneous rIL-2 programs. The role of a maintenance therapy needs further evaluation. To improve these results, combinations of rIL-2 and other drugs or cytokines have been suggested. Preliminary reports of such trials of rIL-2 combined with alpha interferon [8, 9] and with 5-fluorouracil and alpha interferon [10, 11] seem promising.
